
专业多发性骨髓瘤微小残留病
微小残留病指导的新诊断多发性骨髓瘤巩固治疗:MIDAS III期试验的见解
By MedXY|2025年10月1日
在适合移植的多发性骨髓瘤患者中,微小残留病(MRD)指导的巩固策略并未显著提高深度缓解率,这质疑了MRD适应强化治疗的临床价值。
Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.